On August 14, 2014, Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) announced financial results for the second quarter 2014. For the quarter, the company reported no revenues with a net loss of $0.4 million, or $0.03 per share. Net loss for the quarter included $2.0 million in G&A expenses and $1.0 million in R&D expenses. The company reported non-operating income of $3.3 million, mainly due to a decrease in the value of the derivative warrants issued in March 2014.
Immune exited the second quarter 2014 with $3.2 million in cash and cash equivalents. We remind investors that in April 2014, Immune entered into a three-year, $5.0 million revolving line of credit with an existing stockholder, who is related to a member...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|